Home / Pharmaceuticals / Chronic Kidney Disease (CKD) Drugs Market By Drug Class (Antihypertensive, Antihyperlipidemic, Anemia Treatment Drugs, Swelling Treatment Drugs) - Growth, Future Prospects And Competitive Analysis 2017 – 2025

Chronic Kidney Disease (CKD) Drugs Market By Drug Class (Antihypertensive, Antihyperlipidemic, Anemia Treatment Drugs, Swelling Treatment Drugs) - Growth, Future Prospects And Competitive Analysis 2017 – 2025

Published: May 2017 | Report Code: 58454-05-17

Chronic kidney disease is also known as chronic renal disease or chronic kidney failure it is characterized by progressive loss in kidney function over period of time. Factors such as rising in geriatric population, increase in prevalence of CKD and favorable reimbursement policies in some countries are driving the market growth of CKD drugs worldwide.

The report titled “Chronic Kidney Disease (CKD) Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall Chronic Kidney Disease (CKD) Drugs market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on drug class (antihypertensive, antihyperlipidemic, anemia treatment drugs, swelling treatment drugs and other medications) and different geographical regions.

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in global chronic kidney disease (CKD) drugs market, attractive investment proposition and market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:

Geographically, the global chronic kidney disease (CKD) drugs market is studied for the following regional markets:   

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
  • Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global chronic kidney disease (CKD) drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global chronic kidney disease (CKD) drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global chronic kidney disease (CKD) drugs market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.      

Thus, the research study provides a holistic view of the global chronic kidney disease (CKD) drugs market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.   

Chronic Kidney Disease (CKD) Drugs Market

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Chronic Kidney Disease (CKD) Drugs Market Snapshot
2.2 Global Chronic Kidney Disease (CKD) Drugs Market, by Drug Class, 2016 (US$ Bn)
2.3 Global Chronic Kidney Disease (CKD) Drugs Market Share, by Geography, 2016 (Value %)

Chapter 3 Chronic Kidney Disease (CKD) Drugs Market Analysis
3.1 Global Chronic Kidney Disease (CKD) Drugs Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 High prevalence of Chronic Kidney Disease (CKD)
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Chronic Kidney Disease (CKD) Drugs Market

Chapter 4 Global Chronic Kidney Disease (CKD) Drugs Market, by Drug Class
4.1 Overview
4.2 Antihypertensive
4.3 Antihyperlipidemic
4.4 Anemia Treatment Drugs
4.5 Swelling Treatment Drugs
4.6 Other

Chapter 5 Global Chronic Kidney Disease (CKD) Drugs Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.5 Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 AbbVie, Inc.
6.2 Allergan plc.
6.3 Amgen Inc.
6.4 AstraZeneca plc.
6.5 F. Hoffmann-La Roche Ltd
6.6 FibroGen
6.7 GlaxoSmithKline plc.
6.8 Johnson & Johnson
6.9 Keryx Biopharmaceuticals, Inc.
6.10 Kissei Pharmaceutical Co., Ltd
6.11 Pfizer, Inc.
6.12 Sanofi S.A.
6.13 Teva Pharmaceutical Industries Ltd.

List Of Table :

TABLE 1 Market Positioning of Key Players in Global Chronic Kidney Disease (CKD) Drugs Market
TABLE 2 Global Chronic Kidney Disease (CKD) Drugs Market, by Drug Class, 2015 – 2025 (US$ Bn)
TABLE 3 Global Chronic Kidney Disease (CKD) Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 4 North America Chronic Kidney Disease (CKD) Drugs Market, 2015 – 2025 (US$ Bn)
TABLE 5 Europe Chronic Kidney Disease (CKD) Drugs Market, 2015 – 2025 (US$ Bn)
TABLE 6 Asia Pacific Chronic Kidney Disease (CKD) Drugs Market, 2015 – 2025 (US$ Bn)
TABLE 7 AbbVie, Inc.
: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 8 Allergan plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 9 Amgen Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 10 AstraZeneca plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 11 F. Hoffmann-La Roche Ltd: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 12 FibroGen: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 13 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 14 Johnson & Johnson: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 15 Keryx Biopharmaceuticals, Inc. : Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 Kissei Pharmaceutical Co., Ltd: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 Sanofi S.A.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 Teva Pharmaceutical Industries Ltd. : Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

List Of Figures :

FIG. 1 Chronic Kidney Disease (CKD) Drugs Market: Research Methodology
FIG. 2 Global Chronic Kidney Disease (CKD) Drugs Market, by Drug Class, 2016 (US$ Bn)
FIG. 3 Global Chronic Kidney Disease (CKD) Drugs Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Chronic Kidney Disease (CKD) Drugs Market, by Geography, 2016
FIG. 5 Global Antihypertensive Market for Chronic Kidney Disease (CKD) Drugs, 2015 – 2025 (US$ Bn)
FIG. 6 Global Antihyperlipidemic Market for Chronic Kidney Disease (CKD) Drugs, 2015 – 2025 (US$ Bn)
FIG. 7 Global Anemia Treatment Drugs Market for Chronic Kidney Disease (CKD) Drugs, 2015 – 2025 (US$ Bn)
FIG. 8 Global Swelling Treatment Drugs Market for Chronic Kidney Disease (CKD) Drugs, 2015 – 2025 (US$ Bn)
FIG. 9 Global Other Medication Market for Chronic Kidney Disease (CKD) Drugs, 2015 – 2025 (US$ Bn)
FIG. 10 Latin America Chronic Kidney Disease (CKD) Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 11 Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market, 2015 – 2025 (US$ Bn)

Based on drug class, the global chronic kidney disease (CKD) drugs market is segmented as follows:  

  • Antihypertensive
    • ACE Inhibitors
    • Angiotensin-II Receptor Blockers
    • Beta Blockers
    • Calcium Channel Blockers
    • Diuretics
  • Anemia Treatment Drugs
  • Antihyperlipidemic Drugs
  • Swelling Treatment Drugs
  • Other

Chronic kidney disease also known as chronic renal disease, is characterized by a gradual loss of kidney function over time. Factors such as higher prevalence of CKD worldwide, increasing incidence of diabetes and cardiovascular disease and rising geriatric population are driving the market growth of CKD dugs worldwide. According to Centers for Disease Control and Prevention (CDC) more than 10% of adults in the United States affected with CKD, patients with diabetes and hypertension are at higher risk of developing CKD. Approximately 1 of 3 adults with diabetes and 1 of 5 adults with high blood pressure has CKD. It is observed that, in the base year 2016, antihypertensive medication held largest market share, because patients with CKD generally experience high blood pressure. There are different class of medications used to treat high blood pressure in CKD, it is estimated that ACE inhibitors and diuretics are most widely used in market as these are recommended as a first line treatment. Erythropoietin stimulating agents are extensively used in market as anemia is common complication associated with CKD.

Chronic Kidney Disease (CKD) Drugs Market

For the purpose of this study, the global chronic kidney disease (CKD) drugs market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

In the base year 2016, North America dominated the chronic kidney disease (CKD) drugs market and United States is major revenue contributor because factors such as, increase in number of obese and diabetic patients, higher cost of medication, promising pipeline molecule such as ABT-614 (Abbott laboratories), EOS789 (Chugai Pharmaceutical) and upsurge in funding by government agencies and private organizations in healthcare system are driving the market growth of CKD medication in North America. According to Centers for Disease Control and Prevention more than 20 million people in the United States are affected with CKD in United States. Federal and state governmental agencies and various national organizations have developed thorough plans to handle CKD in the United States which would further drive the market growth in North America. Europe is the second largest revenue generating regional market for CKD drugs due to the higher number of affected patients and higher cost of treatment. It is anticipated that Asia pacific will show fastest growth during forecast period due to rising incidence of cardiovascular disorders and diabetes, continuous economic development, increase in health care spending, populous countries and improvement in healthcare infrastructure would contribute the market growth in Asia Pacific during forecast period 2017-2025.

Chronic Kidney Disease (CKD) Drugs Market

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients